verapamil has been researched along with fluphenazine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Cianchetta, G; Cruciani, G; Fravolini, A; Giesing, D; Singleton, RW; Vaz, RJ; Wildgoose, M; Zhang, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brouillette, WJ; Brown, GB; Zha, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beck, WT | 1 |
| Boadle-Biber, MC | 1 |
| Boland, R; Buitrago, C; de Boland, AR; Morelli, S | 1 |
| Dreja, K; Hellstrand, P; Hultgårdh-Nilsson, A; Lindqvist, A; Lövdahl, C; Moses, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for verapamil and fluphenazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for verapamil and fluphenazine
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Fluoresceins; Fluorescent Dyes; Humans; Models, Molecular; Multivariate Analysis; Permeability; Quantitative Structure-Activity Relationship | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
Topics: Ligands; Models, Molecular; Quantitative Structure-Activity Relationship; Voltage-Gated Sodium Channels | 2014 |
Cellular pharmacology of Vinca alkaloid resistance and its circumvention.
Topics: Biological Transport, Active; Cell Line; Cell Survival; Drug Resistance; Fluphenazine; Glucose; Humans; Ion Channels; Leukemia, Lymphoid; Phenotype; Verapamil; Vinblastine; Vinca Alkaloids | 1984 |
Further studies on the role of calcium in the depolarization-induced activation of tryptophan hydroxylase. Effect of verapamil, Tetracaine, haloperidol and fluphenazine.
Topics: Animals; Brain Stem; Buffers; Calcium; Enzyme Activation; Fluphenazine; Haloperidol; Male; Membrane Potentials; Potassium; Rats; Rats, Inbred Strains; Tetracaine; Tryptophan Hydroxylase; Verapamil | 1982 |
The stimulation of MAP kinase by 1,25(OH)(2)-vitamin D(3) in skeletal muscle cells is mediated by protein kinase C and calcium.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcimycin; Calcitriol; Calcium; Calmodulin; Chick Embryo; Egtazic Acid; Enzyme Activation; Fluphenazine; Indoles; Maleimides; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Skeletal; Naphthalenes; Neomycin; Phosphorylation; Protein Kinase C; Tetradecanoylphorbol Acetate; Thapsigargin; Type C Phospholipases; Verapamil | 2001 |
Smooth muscle cell response to mechanical injury involves intracellular calcium release and ERK1/ERK2 phosphorylation.
Topics: Animals; Arteries; Calcimycin; Calcium; Calcium Channel Blockers; Calmodulin; Cell Division; Cell Movement; Cells, Cultured; DNA; Egtazic Acid; Enzyme Inhibitors; Flavonoids; Fluphenazine; Genistein; Intracellular Fluid; Ionomycin; Ionophores; Male; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Octanols; Phosphorylation; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Thapsigargin; Verapamil | 2001 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |